Detecting and profiling measurable residual disease in multiple myeloma patients
Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.
This study is testing a new way to check for leftover cancer cells in multiple myeloma patients who are in remission after a transplant to see how well their treatment is working.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sir Mortimer B. Davis - Jewish General Hospital Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT05530096 on ClinicalTrials.gov |
What this trial studies
This observational study aims to detect and profile measurable residual disease (MRD) in patients with multiple myeloma who are in their first remission and receiving maintenance therapy post-transplant. It utilizes Telo Genomics Technology alongside standard care to monitor MRD levels, which are crucial for assessing treatment efficacy and disease progression. The study will collect deidentified demographic and clinical follow-up data to enhance understanding of MRD prognostics in this patient population.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed diagnosis of multiple myeloma who are transplant-eligible and in their first remission.
Not a fit: Patients who do not meet the inclusion criteria, such as those not in remission or not eligible for transplant, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of multiple myeloma, potentially enhancing patient outcomes.
How similar studies have performed: Other studies have shown promise in using similar methodologies for monitoring MRD in multiple myeloma, indicating a potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed MM diagnosis * Transplant eligible patients in a first remission * Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed) * Availability of deidentified patient's demographic and clinical follow up data * Receiving standard of care treatment * Able to provide informed consent Exclusion Criteria: * Failure to meet inclusion criteria
Where this trial is running
Montreal, Quebec
- Jewish General Hospital — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Rayan Kaedbey — Sir Mortimer B. Davis - Jewish General Hospital
- Study coordinator: Rayan Kaedbey, MD FRCPC
- Email: rayan.kaedbey.med@ssss.gouv.qc.ca
- Phone: 514-340-8222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.